EU agency backs new drugs from GSK, Gilead, Otsuka
22/11/2013 12:11
LONDON, Nov 22 (Reuters) - European regulators said on Friday they had recommended approval of a new drug for HIV from GlaxoSmithKline GSK.L and a novel hepatitis C treatment from Gilead Sciences GILD.O . The European Medicine Agency (EMA) also gave a green light to an Otsuka 4768.T tuberculosis drug, following a review of an earlier rejection. Recommendations for marketing approval by the EMA's Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months. (Reporting by Ben Hirschler; Editing by Kate Kelland) ((ben.hirschler@thomsonreuters.com; +44 20 7542 5082; Reuters Messaging: ben.hirschler.thomsonreuters.com@reuters.net)) Keywords: EUROPE MEDICINES/